These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15944615)

  • 1. Cardiovascular risk prevention in peripheral artery disease.
    Hackam DG
    J Vasc Surg; 2005 Jun; 41(6):1070-3. PubMed ID: 15944615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of risk in peripheral artery disease: recent therapeutic advances.
    Hackam DG; Goodman SG; Anand SS
    Am Heart J; 2005 Jul; 150(1):35-40. PubMed ID: 16084148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
    N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
    Al-Omran M; Lindsay TF
    Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A; Poredos P
    Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
    Robinson JG; Maheshwari N
    Am J Cardiol; 2005 Feb; 95(3):373-8. PubMed ID: 15670547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries.
    Hackam DG; Tan MK; Lin PJ; Mehta PG; Jaffer S; Kates M; Oh M; Grima EA; Langer A; Goodman SG; ;
    J Vasc Surg; 2006 Oct; 44(4):776-81. PubMed ID: 16930931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
    Lloyd GM; Newton JD; Norwood MG; Franks SC; Bown MJ; Sayers RD
    J Vasc Surg; 2004 Oct; 40(4):691-7. PubMed ID: 15472596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.
    Feringa HH; Karagiannis SE; Chonchol M; Vidakovic R; Noordzij PG; Elhendy A; van Domburg RT; Welten G; Schouten O; Bax JJ; Berl T; Poldermans D
    J Am Soc Nephrol; 2007 Jun; 18(6):1872-9. PubMed ID: 17475817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication underuse during long-term follow-up in patients with peripheral arterial disease.
    Hoeks SE; Scholte op Reimer WJ; van Gestel YR; Schouten O; Lenzen MJ; Flu WJ; van Kuijk JP; Latour C; Bax JJ; van Urk H; Poldermans D
    Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):338-43. PubMed ID: 20031859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
    Mancini GB; Etminan M; Zhang B; Levesque LE; FitzGerald JM; Brophy JM
    J Am Coll Cardiol; 2006 Jun; 47(12):2554-60. PubMed ID: 16781387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk in patients with type 2 diabetes.
    Shanks M; Holmes DT; Cermakova L; Frohlich J
    CMAJ; 2005 Apr; 172(9):1160-1. PubMed ID: 15851694
    [No Abstract]   [Full Text] [Related]  

  • 17. Atherosclerotic risk factor control in patients with peripheral arterial disease.
    Rehring TF; Sandhoff BG; Stolcpart RS; Merenich JA; Hollis HW
    J Vasc Surg; 2005 May; 41(5):816-22. PubMed ID: 15886666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of intermittent claudication: the importance of secondary prevention.
    Donnelly R; Yeung JM
    Eur J Vasc Endovasc Surg; 2002 Feb; 23(2):100-7. PubMed ID: 11863326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Office management of peripheral arterial disease.
    Aronow WS
    Am J Med; 2010 Sep; 123(9):790-2. PubMed ID: 20800143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.